ＮＡＮＯホールディングス announced a strategic business alliance with OEP on 17 September and disclosed a third-party allotment of shares on the same day. Trading volume on 18 September rose sharply from the previous day, while the stock price remained range-bound at around ¥100.
On 17 September, ＮＡＮＯホールディングス announced a strategic business alliance with OEP, a US healthcare company. In connection with the alliance, the company stated its intention to conduct a third-party allotment of shares, entering a phase of putting its capital partnership and growth strategy into concrete form.
Trading volume announced on the same day rose sharply to 443,400 shares on 18 September from the previous day. While trading activity increased in the market, the stock price remained range-bound at around ¥100.
The results announced on 2026年8月7日 are included as a summary of the earnings report. In the first quarter of the fiscal year ending March 2027, net sales rose 363.6% year on year to approximately ¥35.7 million, but higher expenses led to an operating loss of approximately ¥276 million and a quarterly net loss attributable to owners of the parent of approximately ¥281 million, with losses widening. The full-year earnings forecast was not disclosed, and no dividend is expected to be paid.
Key points for monitoring future earnings include the execution of investments on the investment platform and the accumulation of sales revenue, as well as progress in clinical development and the feasibility and timing of licensing out. The continuation of raw-materials and pharmaceutical sales, along with trends in the financing environment, may also affect business growth.